Systemic Sclerosis With Interstitial Lung Disease

Slides:

Advertisements

Similar presentations

Update in ILD: Current Approaches to IPF Andrew M. Tager, M.D.

Advertisements

Interstitial lung disease in systemic sclerosis

Coinvolgimento polmonare nella sclerosi sistemica Marco Matucci Cerinic Departments of Rheumatology AVC BioMedicine & Division of Rheumatology AOUC Medicine,

CREST J. Ryan Altman, MD AM REPORT 9 December 2009.

Acute Respiratory Distress Syndrome Sa’ad Lahri Registrar Department of Emergency Medicine UCT/ University of Stellenbosch.

INTERSTITIAL LUNG DISEASE

IDIOPATHIC PULMONARY FIBROSIS

Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.

IDIOPATHIC PULMONARY FIBROSIS. BASICS in IPF CLASSIFICATION OF INTERSTITIAL LUNG DISEASE OR DIFFUSE PARENCHYMAL LUNG DISEASE.

Do outcomes of surgical treatment for Achalasia depend on the manometric subtype? Keliang Xiao 1, Oscar Crespin 2 Roger Tatum 2, Ana V. Martin 2,Saurabh.

Exercise Testing – clinical utility Sudhir Rao Respiratory registrar.

BAL in the diagnosis of ILD Athol Wells Royal Brompton Hospital London, UK.

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, in Patients with.

Should it be viewed as a single entity? Hypersensitivity pneumonitis Should it be viewed as a single entity? Venerino Poletti versus Athol Wells.

A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* N Engl J Med 2010.

CA 19-9 in Patients with Pulmonary Fibrosis Department of Rheumatology Doohyun Woo.

Usual interstitial pneumonia: an overview Ola El-Zammar, M.D. Assistant professor of pathology SUNY Upstate Medical University, Syracuse, NY.

CHEST 2013; 144(1):234–240 R1 정수웅 Christopher J. Ryerson, MD ; Thomas Hartman, MD ; Brett M. Elicker, MD ; Brett Ley, MD ; Joyce S. Lee, MD ; Marta Abbritti,

Scleroderma Lung Disease Robert Schilz DO, PhD University Hospitals Case Medical Center Cleveland, OH.

How Charitable Organisations Support Research Presentation By: Sue Farrington Monday 10th October 2016.

Fig 1: Skin thickening and sclerodactyly Fig 2: Digital tip ulcers

TBCRC (the translational breast cancer research consortium) 005 Prospective study

Volume 148, Issue 5, Pages (November 2015)

Patient Case 1 Patient Case 1: PET/CT Scan.

Exploring Early Combination Therapy in PAH

More Than Meets the Eye: Identifying Who Is at Risk for NASH

Assessing the Impact: New Data in T790+ NSCLC

Changing the IBD Paradigm

UNDERSTANDING RISK STRATIFICATION IN PAH:

What Predicts Disability Progression in Multiple Sclerosis?

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

Metastatic Renal Cell Carcinoma

Clinical Cases in Glaucoma Treatment

Patient Demographics Referred by:

Name: Age: Sex: Presenting History Symptom progression Current status:

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Challenges in Managing Progressive Multiple Sclerosis

Decision-making in the eRA of Treating to Target

Evaluation of the Patient With HCV Infection

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Activity Goals. Activity Goals Case Presentation.

Novel Therapies for the Treatment of MS

Multidisciplinary Perspectives on Interstitial Lung Diseases

Primary Biliary Cholangitis

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Treating to Target in MS

Atelectasis, acute respiratory distress syndrome & pulmonary edema

Volume 146, Issue 6, Pages (December 2014)

Imaging to Assess IPF Progression A Case-Based Approach

Practical Guidance on the Management of Pan-Negative NSCLC

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Pulmonary 1, Case 6 56-year-old man with progressive dyspnea and bilateral infiltrates in lung.

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Improving Outcomes in Patients With SSc-ILD

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Cutaneous T-Cell Lymphoma: Disease, Diagnosis, and Therapy

Patient case study 2—fibrotic uILD in the setting of IPAF

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

Targeting Apoptosis in AML

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

This schematic view of the morpho-functional unit of the lung (alveolus) depicts the main differences in cellular composition in idiopathic pulmonary fibrosis.

Pulmonary Arterial Hypertension and Hospitalizations

Early Diagnosis and Management of SSc-ILD

Working Together to Diagnose Idiopathic Pulmonary Fibrosis

Subtypes of ILD in pre-MDT and post-MDT cohorts.

Presentation transcript:

Systemic Sclerosis With Interstitial Lung Disease

Overview

Major Subsets of SSc

Overview of Major SSc Complications

Survival in SSc Is Determined by Subset and Organ-Based Manifestations

Differences Between Diffuse and Limited SSc: Cumulative Frequency of Major Organ-Based Complications

Pathogenesis of SSc

Cellular Pathogenesis of Fibrotic Lung Injury

Microarray Analysis of SSc Lung Tissue

Genes With > 10-Fold Overexpression in SSc-ILD vs Control

Esophageal Dilation and ILD in SSc

Impact of Pulmonary Complications on Survival in SSc

Patterns of ANA Reactivity in SSc

Autoantibody Reactivity Predicts Outcomes in SSc

Multiple Mechanisms for Dyspnea in SSc

Histological Classification of IIPs in CTD

HRCT Assessment in SSc

HRCT Scoring System: Quantification of Extent of ILD

Histological Classification of SSc-ILD

Impact of Histological Subtype on Outcome in SSc-ILD

A Simple Staging System for Treatment Decisions in SSc-ILD

Disease Extent: Impact on Survival

Epithelial Injury As a Marker of Progression in SSc-ILD: Serum KL-6

Short-Term Pulmonary Function Trends Predict Mortality in SSc-ILD

Decline in DLco and Kco Predicts Outcome at 24 Months

Association of Severe Lung Fibrosis in SSc

Management of Lung Fibrosis in SSc: Royal Free Hospital Protocol

Oral Cyclophosphamide in SSc-PF: The SLS I Study

SLS II Outcome Data: Frequency Distribution of Changes from Baseline to 24 Months in % Predicted

Targeted Therapy in SSc

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)